Insmed Inc (INSM)vsTscan Therapeutics Inc (TCRX)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
TCRX
Tscan Therapeutics Inc
$1.03
-0.96%
HEALTHCARE · Cap: $58.61M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 5773% more annual revenue ($606.42M vs $10.32M). TCRX leads profitability with a 0.0% profit margin vs -2.1%. TCRX earns a higher WallStSmart Score of 40/100 (F).
INSM
Hold39
out of 100
Grade: F
TCRX
Hold40
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Reasonable price relative to book value
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
2.9% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : TCRX
The strongest argument for TCRX centers on Price/Book.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : TCRX
The primary concerns for TCRX are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while TCRX is a value play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
TCRX is growing revenue faster at 2.9% — sustainability is the question.
TCRX generates stronger free cash flow (-32M), providing more financial flexibility.
Bottom Line
TCRX scores higher overall (40/100 vs 39/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Tscan Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Tscan Therapeutics Inc (TCRX) is a clinical-stage biotechnology firm that specializes in advancing immunotherapy through its proprietary T cell receptor (TCR) discovery platform, targeting specific cancer antigens to offer precision medicine solutions in oncology. The company is focused on developing innovative TCR-based therapeutics aimed at translating scientific advancements into effective treatment options for various cancers and diseases, ultimately improving patient outcomes. With a strong therapeutic pipeline and a comprehensive intellectual property portfolio, Tscan Therapeutics is well-positioned to become a leader in the rapidly evolving landscape of T cell-based therapies.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?